Chinese expert consensus on precision diagnosis and treatment of refractory tumors.
1/5 보강
Refractory tumors, including rare and treatment-resistant malignancies, pose major challenges due to genomic and intra- and inter-tumoral heterogeneity.
APA
Wang L, Zhang Y, et al. (2026). Chinese expert consensus on precision diagnosis and treatment of refractory tumors.. Critical reviews in oncology/hematology, 218, 105109. https://doi.org/10.1016/j.critrevonc.2025.105109
MLA
Wang L, et al.. "Chinese expert consensus on precision diagnosis and treatment of refractory tumors.." Critical reviews in oncology/hematology, vol. 218, 2026, pp. 105109.
PMID
41485634 ↗
Abstract 한글 요약
Refractory tumors, including rare and treatment-resistant malignancies, pose major challenges due to genomic and intra- and inter-tumoral heterogeneity. The Molecular Tumor Board provides a multidisciplinary model for precision oncology. To address the lack of consensus, the China Consortium for Precision Diagnosis and Therapeutics in Refractory Tumors (CCPT) developed evidence-based guidelines. Building on established frameworks and clinical expertise, CCPT also introduced a Chinese-specific classification system, together with recommendations on multi-omics testing, personalized therapy, combination strategies, dose optimization, and data-sharing, to standardize practice and advance integrated precision care.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Dual-stage pulmonary nodule detection in CT scans via cross-layer attention and adaptive multi-scale 3D CNN.
- Self-assembly driven nano-salinomycin for high-efficiency cancer immunotherapy by reticulum stress mediated stemness suppression.
- Predictive prioritization of enhancers associated with pancreatic disease risk.
- DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.